Just Launched: My Mito Story

As part of UMDF’s commitment to raising the voice of patients, Ashton Fairchild Ferguson, a 23-year-old Univerity of California – San Diego graduate, is sharing his story about living with Cystic Fibrosis and a mitochondrial deletion and depletion disease. Said Ashton “I majored in communications and I wish to use the skills I learned to help patients like me in the medical field. These two diseases have greatly altered my path in life and I would like to share how and why.” In this 5-part blog, Ashton talks about his diagnostic journey, daily life, and hopes for the future. A new blog will be posted weekly starting August 31, 2024.

Click the + button to the right to expand individual blog posts ↓

Ashton Ferguson's Story: Part 1, Childhood

My name is Ashton Fairchild Ferguson and I am a 23-year-old UCSD graduate. I have been a Cystic Fibrosis (CF) patient from birth and I was diagnosed with a single large mitochondrial deletion and depletion disease when I was in my late teens. Cystic Fibrosis is a genetic disease that affects the lungs and just about every organ in your body. I have liver disease, diabetes, infertility, high blood pressure, digestive issues, and congested lungs just because of CF.

I am writing this as a patient in my early twenties who has a mitochondrial disorder. Hopefully, this project will instill some insight and hope for those who are new to this side of the medical world. Despite my double diagnosis, I am mostly a success story and I want to show that these diseases don’t have to be the end of life as they know it. Here, I would like to record what life was like before I even knew I had a mitochondrial deletion disease, starting from birth into my mid-teens.

I was born prematurely because there was something very wrong going on in my gut, so my mom endured a C-section and I was cut open at the stomach to reveal my intestines in a knot. From that, I have a scar that reaches across my belly to this day. They figured out I had CF by doing a genetic blood test. My time after birth was horrid according to my parents and they were even more worried because the life expectancy of a CF patient at the time of 2001 was in the late twenties. My parents knew nothing about CF except my mom had a teacher in high school who would breathe from an oxygen tank during breaks and died of CF not long after she graduated. So yeah, not very good prospects. CF patients burn more calories than most people do so when I was a baby, I was given a G-tube and I was exclusively fed through that rather than my mouth. A G-tube is a small device the length of a thumb that is put in a hole in my abdomen that was surgically created. This device can connect to a tube that can feed it water or other forms of nutrients and it will go straight to my belly. Yes, this sounds gross, and it is, but I’ve had this all my life and the only maintenance that needs to be done for it is to change it out every six months or so. Changing it out is simple. There is a water balloon in the G-tube that keeps it secure in my belly so by sucking that water out, it can easily be pulled out with some lubricant and replaced with a new one. The only time I’ve had a mishap with a G-tube was in grade school when I fell while playing soccer and it fell out. The problem is that if there isn’t a new one inserted soon enough, the hole in my belly will close up. So my mom raced over to my school and put a new one in right on time. It’s safe to say that I don’t recommend contact sports if you are using a G-tube. Using the G-tube had unforeseen effects on me where I actually grew up with practically no appetite so I didn’t enjoy eating nor did I feel hunger. Things have changed now, but we’ll get to that.

As a child, I was given tons of treatments to do to keep me as healthy as possible. The amount of pills I’ve had to take has only increased over the years, fifty being my current daily dose. This was mostly because we didn’t know everything that was wrong with my body from the beginning so new medication was added often. The most prominent treatment for CF is a vibrating vest that shakes the mucus out of my lungs so I can cough it out. When I first tried this out as a child, my lips turned blue from fear of the shaking. It took me a while to get used to this. Now, I just play video games or do homework during them for thirty minutes twice a day as if it’s no big deal.

Despite all of the treatments I did at a young age, I was still very sick. I distinctly remember walking around school with an IV pole during first grade. I was never treated differently because of this, but it was the first time in my life that I felt I was very different from everyone else. I don’t remember being sick as a kid. Maybe I blocked it out, but I do remember what my parents finally did about it. They took me to the CF clinic at the University of Minnesota in Minneapolis (I lived in Kansas at the time) and the people there gave me different treatments to do. Since that appointment, I have become much healthier. My parents call it the Minneapolis protocol.

My problems didn’t end there. As a ten-year-old, my CF didn’t progress much. However, there was still the looming threat of my low life expectancy, so my parents turned me into a mascot for the Cystic Fibrosis Foundation ever since I was a baby. I gave little speeches and went on fundraising walks quite often as a child, but I hadn’t yet grasped how important this was. Later in my early teens, a pharmaceutical company called Vertex asked me to cut the ribbon on their new facility that promised to produce new drugs for the CF patient population.

My mom was ecstatic about this, but I just saw this as another thing to be dragged into – until I saw the building. The place is shaped like lungs from a bird’s eye view and there are indoor chandeliers that look like the CF genome. I remember the huge crowd of people taking pictures and how happy my mom was.  It made me think, “OK, there’s something I don’t know here.” It turns out the lead scientist behind all of this, Paul Negulescu, has known my mom since I was a baby. Back then, he promised to take a big step toward an eventual cure one day. Well, this building was it. Just a few years later, Vertex released drugs in pill form that got me to cough out gray matter that had been sitting in my lungs for all my life and the drugs only got better from there. Their most recent drug, Trikafta, was released in 2019. It’s the only drug I can genuinely call a miracle drug. It is effective for 90% of the CF population. It doubled people’s lung function, stabilized their organs, and even allowed patients to have children. This is exactly what I spent my early life fundraising for, I just didn’t know it. Trikafta has a positive effect on me but not nearly as much as it has on others. I still have to do all of my treatments, I have weight gain and blood pressure issues, and I am still infertile. Nowadays, the Cystic Fibrosis Foundation (CFF) is a billion-dollar organization so I felt they didn’t really need my help anymore. Even so, I was famous enough to be on news channels and I even met someone on a dating app who recognized me and knew my story.

Unfortunately, she had CF too so we couldn’t go any further. There’s a weird bacterial reaction between CF patients where they must not stay near each other or they risk getting really sick. The bacteria that are exhaled from a CF patient’s lungs are dangerous for other patients to breathe in. I don’t know much about the subject since I have never caught anything from another CF patient. I also haven’t been able to meet other people with my disease in person. For a long time, this felt like a normal fact of life that didn’t bother me. That is until very recently when the woman with CF I mentioned earlier reached out to me on a dating app since she recognized my name. It sucked knowing there was no chance for us to date unless we wanted to risk getting really sick. Overall, because of this strange bacterial thing, CF patients can’t get to know each other in person, and trying to do it remotely just doesn’t seem right. By the time Vertex started making these drugs, the average life expectancy had risen yet people are still dying from CF complications.

COMING NEXT WEEK … let’s go back to my pre-teens and talk about food — and my mito diagnosis.

 

What is KSS?

Kearns-Sayre syndrome (KSS) is a mitochondrial DNA deletion syndrome that impacts multiple systems of the body. It is a rare disorder, affecting an estimated 1.6 out of 100,000 individuals[1]. Males and females are affected in equal numbers.

Classical Kearns-Sayre syndrome is defined by three features [1,2]:

  1. weakness of the eye muscles (chronic progressive external ophthalmoplegia (CPEO) and droopy eyelids (ptosis)
  2. degeneration of the pigmented cell layer in the back of the eye (pigmentary retinopathy)
  3. cardiac conduction block

In addition, patients often develop difficulty swallowing, nasal speech, limb muscle weakness, and incoordination (ataxia). KSS gradually worsens over time. Unfortunately, no one has identified a means of stopping KSS, and prognosis depends on disease severity. However, many individuals with the disorder may live well into adulthood[2]. Early diagnosis and interventions that address some of the symptoms of KSS may be particularly helpful in this regard.

What causes KSS?

KSS is caused by large deletions of mitochondrial DNA. The specific size and sequence of DNA deleted varies from individual to individual; however, many have a 5 kilobase deletion (the ‘common deletion’).

In approximately 90% of KSS cases, the deletions have appeared by chance[3]. Inheritance of a KSS-causing mutation is extremely rare; a woman with CPEO or KSS with a single mtDNA deletion may transmit the mutation to about 4% of their children.

What are the symptoms of KSS?

Chronic progressive external ophthalmoplegia (CPEO) is one of the key features of KSS. Its symptoms include:

  • drooping eyelids (ptosis)
  • paralysis of the muscles that control eye movement

Additional key feature of KSS are: degeneration of the pigmented cell layer in the back of the eye (pigmentary retinopathy) and cardiac conduction block.

KSS also often includes following manifestations[4]:

  • difficulty swallowing and limb muscle weakness often accompany the eye abnormalities
  • elevated cerebrospinal fluid (CSF) protein
  • incoordination (ataxia)
  • depression
  • impaired cognition

Kearns-Sayre patients usually have multi-organ system involvement and may suffer from some of the mitochondrial problems depicted in Figure 1 (image coming soon) (4) .

In particular, individuals with KSS may have[5,6]:

  • short stature
  • failure to thrive
  • hearing loss
  • folate deficiency
  • diminished muscle tone (hypotonia)
  • delayed puberty
  • intellectual disability
  • seizures
  • diabetes and other endocrine problems
  • renal impairment

How do I know if my loved one has KSS?

KSS diagnosis is based on clinical features accompanied by the presence of a mitochondrial DNA deletion.

If you or your loved one shows signs of KSS, their healthcare provider may perform the following to establish a diagnosis:

  • a muscle sample (biopsy) or buccal swab to look for mitochondrial DNA deletion (A muscle biopsy can confirm mitochondrial abnormalities on microscopic study)
  • an echocardiogram
  • ophthalmological examination
  • measurements of the level of lactic acid and pyruvate in the blood
  • an electrocardiogram
  • an electromyogram
  • a brain MRI
  • hearing test
  • blood tests to check for evidence of mitochondrial dysfunction, endocrinopathies (especially diabetes and growth hormone deficiency), and kidney dysfunction.
  • measurements of the level of protein in the cerebrospinal fluid (CSF)

What are the treatments for KSS?

Options for managing KSS symptoms include:

  • surgery or special glasses to correct drooping eyelids
  • physical and occupational therapy to improve muscle strength and balance
  • a pacemaker for heart conduction block
  • a cochlear implant for hearing problems
  • folinic acid for cerebral folate deficiency
  • hormone replacement for short stature
  • insulin for diabetes
  • supplements such as coenzyme Q10, B complex vitamins, alpha lipoic acid, or L-carnitine

Regular checkups with specialists are critical for those with KSS. Monitoring for signs of heart problems is particularly important since sudden cardiac events, in particular cardiac conduction block are a common cause of death in these individuals[6]. Onset of slow heart rate, heart racing, or fainting spells require an urgent emergency room visit.

Are there any clinical trials for KSS?

Currently KSS clinical trials focus on exercise intolerance (generally patients with CPEO+ and not classical KSS).

To see what trials you may qualify for, visit our Clinical Trials page – which also included a Clinical Trials Finder Tool. We also highly encourage you to join our patient registry, mitoSHARE, where we are actively recruiting KSS families.

How can my family cope with KSS?

We are here to help. UMDF serves a number of families coping with KSS. We suggest you reach out to our Support & Education Team – online, via email at support@umdf.org or phone at (888) 900-6486 – who can suggest a host of resources including doctors,  KSS specific support meetings, and more. They’ll also connect you with a UMDF ambassador, likely a fellow KSS patient or family member, who can help support and guide you through your questions.

 

What are the next steps if my loved one has KSS?

  • Get Support
    Connect with our Support & Education Team online, via email at support@umdf.org or phone at (888) 900-6486.
  • Check our Clinical Trials Finder
    Use our Clinical Trials Finder to see if you qualify for any clinical trials.
  • Join our patient registry, mitoSHARE
    We are actively recruiting KSS families to participate in our patient registry, mitoSHARE. Patient registries like mitoSHARE are an integral part in charting a course toward treatments and cures for KSS and other mitochondrial diseases. There are currently over 30 active mitochondrial disease clinical trials. Next generation patient registries like mitoSHARE are an integral part of expanding that number.
  • Become an advocate
    Ask your representatives to prioritize mitochondrial disease research and support via the UMDF Advocacy Center. We’ll send regular action items so you – and your friends and family – can let Congress know where we need their support. Click here to sign up.

What is UMDF doing about KSS?

UMDF is helping chart a path toward treatments and eventual cure of mitochondrial diseases like KSS through:

  • Research & Funding: UMDF has provided more than $15 million in research funding to find treatments for diseases like KSS. UMDF advocacy has helped secure an additional $55 million in federal funding via the Department of Defense and National Institutes of Health.
  • Data: Over two decades ago, UMDF pioneered patient registries for the mitochondrial disease community. Today, our next generation patient registry, mitoSHARE, is helping chart a path toward the treatment and eventual cure of mitochondrial diseases.
  • Patient Support: Thousands of families just like you depend upon UMDF for support and education on diseases like KSS. Attendance at our support meetings annually tops 7,000, including disease specific support meetings for families.
  • Clinician Support: To help educate clinicians on diseases like KSS, we feature monthly Bench to Bedside clinician seminars, host the annual Mitochondrial Medicine Symposium, support the Mitochondrial Care Network, and educate clinicians on our Mito U platform.

I didn’t find what I’m looking for here. What should I do?

UMDF Is here to help. Contact the Support Line at (888) 900-6486 weekdays from 8:00am to 5:00pm EST to connect with our Patient Concierge. Or, via email contact support@umdf.org.

References

  1. Remes AM, Majamaa-Voltti K, Kärppä M, et al. Prevalence of large-scale mitochondrial DNA deletions in an adult Finnish population. Neurology. 2005;64(6):976-981. doi:10.1212/01.WNL.0000154518.31302.ED
  1. https://www.omim.org/entry/530000
  1. Björkman K, Vissing J, Østergaard E, et al. Phenotypic spectrum and clinical course of single large-scale mitochondrial DNA deletion disease in the paediatric population: a multicentre study [published online ahead of print, 2021 Dec 6]. J Med Genet. 2021;jmedgenet-2021-108006. doi:10.1136/jmedgenet-2021-108006
  1. Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM. 2016 Mitochondrial diseases. Nat Rev Dis Primers. 2016 Oct 20;2:16080
  1. Shemesh A, Margolin E. Kearns Sayre Syndrome. [Updated 2021 Aug 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482341/
  1. Goldstein A, Falk MJ. Mitochondrial DNA Deletion Syndromes. 2003 Dec 17 [Updated 2019 Jan 31]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1203/
  1. Grady JP, Campbell G, Ratnaike T, et al. Disease progression in patients with single, large-scale mitochondrial DNA deletions. Brain. 2014;137(Pt 2):323-334. doi:10.1093/brain/awt321
  1. Khambatta S, Nguyen DL, Beckman TJ, Wittich CM. Kearns-Sayre syndrome: a case series of 35 adults and children. Int J Gen Med. 2014;7:325-332. Published 2014 Jul 3. doi:10.2147/IJGM.S65560